Promising ichthyosis drug trial stalls after just 5 patients

NCT ID NCT04697056

Terminated Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a drug called imsidolimab (ANB019) in people with ichthyosis, a condition that causes dry, scaly, and red skin. The trial aimed to see if the drug could improve skin symptoms compared to a placebo. However, the study was stopped early and only enrolled 5 participants, so we cannot draw firm conclusions about its effectiveness or safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: imsidolimab (a lab-made antibody given as an injection)
What this could lead to: If it works, this could point toward a treatment that reduces skin redness and scaling in people with ichthyosis.
What could go wrong: The trial was terminated early with only 5 participants, so results are very limited. It is unclear if the drug is effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ICHTHYOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ichthyosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ICHTHYOSIS

Contacts and locations

Show contact details

Locations

Site 101

Chicago, Illinois, 60611, United States
Site 102

Columbus, Ohio, 43215, United States
Site 104

New Haven, Connecticut, 06519, United States
Site 105

Salt Lake City, Utah, 84132, United States
Site 106

Palo Alto, California, 94304, United States
Site 107

San Antonio, Texas, 78218, United States
Site 112

Miami, Florida, 33125, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.